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A simple purification approach of the recombinant hirudin variant 3 from the Bacillus subtilis was 
established, by which the hirudin could be purified to the purity of 95% through one-step 
chromatography with the total recovery rate of 83.9%. A modified Markwardt thrombin titration method 
for measuring hirudin activity was also set up. Briefly, a series of concentrations of thrombin was 
prepared and titrated to hirudin sample, respectively and the anti-thrombin activity-range of hirudin was 
narrowed down by several thrombin solutions at high or low concentration and the optimum group of 
thrombin concentrations was determined for titration of the hirudin sample. In this modified method, 
the hirudin activity was determined more accurately, concisely and promptly than the classic Markwardt 
method. 
 





Since recombinant hirudin variant was expressed from 
Escherichia coli in 1986, intensive research had been 
performed on large scale of production and clinic 
application of hirudin (Harvey et al., 1986; Greinacher 
and Warkentin, 2008; Fischer et al., 2004). Purification is 
the most expensive step in the product process of 
hirudin. In the previous reports, at least three steps of 
chromatography were always employed, including 
reversed-phase chromatography in which organic solvent 
with side effect to patients was used as eluent (Tan et al., 
2002; Rosenfeld et al., 1996; Scacheri et al., 1993; Zhou 
and Zhang, 2004; Bi et al., 2001). Therefore, these 
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process (Shi et al., 2006). Recently, a low cost two-step 
chromatography process for hirudin purification was 
described by Chen et al. (2009). In this study, we 
established a more simple purification approach of the 
recombinant hirudin variant 3 (rHV3) which consist of an 
efficient pretreatment of the fermentation broth and a 
one-step chromatography. 
The importance of recombinant hirudin as an hirudin 
also necessitate the development of efficient and 
antithrombotic agent and large-scale production of the 
economical method for the quantification of its biological 
activity. Colorimetric methods described by Chang et al. 
(1983) and Iyer and Fareed (1995) needed expensive 
chromogenic substrates and the linear range of the assay 
was too narrow. Rayleigh scattering method described by 
Zhou et al. (1997) needed expensive fluorescence spec-
trophotometer and the standard curve of hirudin should 
be set up. Thrombin titration method established by 
Markwardt (1970) was the classic method to determine 
the activity of hirudin. This method was convenient and 
economical which was employed widely, but repeatability 
and   accuracy   were  limited.  In  this  study,  a  modified  




Markwardt method was set up for measuring hirudin 




MATERIALS AND METHODS 
 
Reagents and instruments 
 
Fibrinogen and thrombin were from Shanghai Institute of Biological 
Products. Dry powders of Hirudo medicinalis Linnaeus and 
Whitmania pigra were from Shanghai Center of Research and 
Development of New Drugs. Normative hirudin was from Sigma 
Company. Chromatography media preassemble column, liquid 
chromatography AKTA Purifier 10 and 100 were all bought from 
Swedish Amersham Company. 
 
 
Determination of hirudin purity 
 
Hirudin purity was determined by high performance liquid 
chromatography (HPLC) with Sephasil Peptide C18 preassemble 
column and purity was expressed as “area of hirudin absorption 
peak/combined area of all peak”, as described previously by Chen 
et al. (2009). 
 
 
Pretreatment of fermentation broth 
 
Cultured medium of the rHV3 was separated from the Bacillus 
subtilis cells by continuous flow centrifugation and 50% trichlo-
roacetic acid was added until pH value reaching 2.5, then the 
unwanted proteins were precipitated by heating at 100°C for 30 
min. The supernatant was kept after centrifugation and the pH value 
of the supernatant was adjusted to 4.0 by the saturated NaOH 
solution, then the proteins were precipitated by (NH4)2SO4 with 90% 
saturation and the precipitated proteins were washed by solution of 
(NH4)2SO4 with 90% saturation twice. Finally, the hirudin activities of 
the samples with pre-and post-treatments were determined and 





Sephacryl S-100 was used to purify recombinant hirudin. 
Equilibrium and elution buffer was: 50 mM phosphate buffer (pH 
7.0) + 0.15 M NaCl. The flow rate was set at 1.1 ml/min and the 
volume of applied sample which came from dissolution of the 
proteins precipitated by (NH4)2SO4 was 10 ml. Absorption peaks 
were collected and identified, furthermore, specific activity, 
purification multiple and activity recovery rate were calculated. The 
purity of collected sample was determined by HPLC. 
 
 
Samples and reagents preparation for thrombin titration 
 
0.5% fibrinogen buffer was prepared in 0.05 M Tris-HCl (pH7.4, 
containing 0.05 M NaCl). Thrombin concentration gradients were 
prepared with 20 NIH/ml as benchmark concentration (1 times), 40 
NIH/ml as 2 times, 100 NIH/ml as 5 times, 200 NIH/ml as 10 times, 
400 NIH/ml as 20 times and so on. 5 µl(20 NIH/ml, 1 times) was set 
as a 1 titration volume (1 V), 5 µl(40 NIH/ml, 2 times) was set as a 2 
titration volume (2 V), 5 µl (100 NIH/ml, 5 times) was set as a 5 
titration volume (5 V) and so on. 
Two kinds of dry leech powder were soaked by physiological 
saline for 30 min, then after centrifugation, the supernatants of H. 
medicinalis Linnaeus and W. pigra were named as titration sample 





the B. subtilis was named as titration sample C. Normative hirudin 





According to the method described by Markwardt (1970), one test 
tube (0.75 × 10 cm) containing 200 µl of 0.5% fibrinogen solution 
mixed with 50 µl sample was incubated in 37°C water for 5 min, 
then 5 µl of 5 times thrombin solution (5 V) was added to the 
mixture in the test tube, if coagulation of the fibrinogen in the test 
tube did not happen in 1 min, another 5 µl of 5 times thrombin 
solution was added, till coagulation happened in 1 min and the total 
titration volume and activity of the thrombin employed in the titration 
were calculated. 
In the modified thrombin titration method, the mixtures all 
containing 200 µl of 0.5% fibrinogen solution and 50 µl sample in 
several little test tubes (0.75 × 10 cm) were incubated at 37°C water 
for 5 min, then one tube was added with 5 µl of 5 times thrombin 
solution, if the mixture coagulated in 1 min after rapidly shaken up, 
the activity should be below 10 ATU/ml (for example, <5 V of 
titration volume), so another tube would be added with 5 µl of 1 
times thrombin solution, if the mixture did not coagulate in 1 min, 
another 5 µl of 1 times thrombin solution will be added, until the 
mixture coagulated in 1 min, the total titration volume and activity 
was calculated. After adding 5 µl of 5 times thrombin solution, if no 
coagulation happened in 1 min, another 5 µl of 20 times thrombin 
solution was added. if no coagulation happened in 1 min, another 5 
µl of 20 times thrombin solution was added subsequently, if 
coagulation happened in 1 min after the rapid mixture, the thrombin 
titration volume should be between 25 and 45 V. Therefore, another 
test tube would be titrated with 5 µl of 20 times thrombin solution 
and 5 µl of 10 times thrombin solution, if coagulation happened in 1 
min after the rapid mixture, the thrombin titration volume should be 
between 25 and 30 V. At last steps, 5 µl of 20 times thrombin 
solution and 5 µl of 5 times thrombin solution were added to 
another test tube, then, 5 µl of 1 times thrombin solution was added 
until coagulation happened. In this way, the anti-thrombin activity-
range of the hirudin sample was narrowed down by several 
thrombin solutions at proper concentration and the optimum group 
of thrombin concentration was determined for titration of the hirudin 
sample at last. Anticoagulation activity of the sample (ATU/ml) was 
the 20 times of the total activity of the thrombin employed in the 
titration. Titration of every sample was repeated seven times and 





Pretreatment of fermentation broth 
 
Almost 98.8% of the impurity protein of the fermentation 
broth was removed by pretreatment of heating at both 
100°C and pH 2.5 for 30 min and the purification multiple 
and recovery rate of the rHV3 protein was 22.9 and 95%, 
respectively (Table 1). Then, pH was adjusted to 4 
(isoelectric point), after precipitation and subsequent 
wash by (NH4)2SO4 with 90% saturation, the total 
purification multiple and recovery rate were 23.9 and 





After gel filtration chromatography (Figure 1), the purity of  



















Fermentation supernatant 1425.6 65581.2 46 100 1 ― 
Treatment at 100°C and pH 2.5  59.1 62302.2 1053.4 95 22.9 ― 
Precipitation by ammonium sulfate 53.8 59187.2 1099.4 90.3 23.9 ― 










final product could reach 95% assayed by HPLC (Figure 
2), with 93% recovery rate and 1.14 purification multiple 
for this chromatography step (Table 1). Seeing from the 
chromatography, the impure peaks that appeared in salt 
peaks or after them mainly were pigments or degraded 
small-peptide fragments. The SDS-PAGE analysis of the 





Titrate was done following the same samples by 
Markwardt method and by the improved method to 
compare the process and merit of these two methods. 
According to the method described by Markwardt, the 
mean values of the activities of sample A, B, C and D 
were 50±9.1, 10±0, 136±15.2, 105±5.6, respectively as 
shown in Figure 4.  
With the modified thrombin titration method, one tube 
was added with 5 µl of 5 times thrombin solution, but the 
mixture did not coagulated in 1 min after rapidly shaken 
up, then 5 µl of 20 times thrombin solution was added, no 
coagulation happened in 1 min, so another 5 µl of 20 
times thrombin solution was added in this mixture, also,










no coagulation happened in 1 min, then another 5 µl of20 
times thrombin solution was added and the mixture 
coagulated in 1 min after rapid shake, that is to say, 
thrombin volume was between 45 and 65 V. Thereafter, 
another test tube was added with 5 µl of 40 times 
thrombin solution and 5 µl of 10 times thrombin solution, 
but no coagulation happened in 1 min after rapid shake 
and 5 µl of 2 times thrombin solution, no coagulation and 
5 µl of 1 times thrombin solution, also no coagulation, 
after 6 times with 5 µl of 1 times thrombin solution, little 
floccule happened, this could be regarded as coagu-
lation, because no big agglomerate happened after 
continuative titration, so the total titration volume was 
regarded as 59 V. But the accuracy was low with too 
many times of titration, so another test tube was added 
with 5 µl of 40 times thrombin solution and 5 µl of 10 
times thrombin solution, no coagulation and 5 µl of 5 
times thrombin solution, also no coagulation and 5 µl of 1 
times thrombin solution, then coagulation happened in 1 
min after shake, as a result, the total titration volume was 
56 V, for example, 5.6 ATU, therefore, the activity of the 
sample C was 112 ATU/ml. This result was repeated 7 
times, with the mean value and the standard deviation 
(SD) being 112.3 and 2.3, respectively, as shown in 
Figure 4. With the same improved thrombin titration 
method, the mean values of sample A, B and D 
were44±1.6, 2±0 and 98±1.8, respectively, as shown in 
Figure 4. When the estimated hirudin activity was high, 






Pretreatment of fermentation broth was very important 
step in protein purification process; unfortunately, many 
researchers often hasten to employ chromatography 
method without careful consideration of protein 
characteristic and preliminary isolation method (Marshak 
et al., 1996). In the previous report, little attention was 
paid to the pretreatment of fermentation broth (Tan et al., 
2002; Rosenfeld et al., 1996; Scacheri et al., 1993; Bi et 
al., 2001; Shi et al., 2006; Kochanowski et al., 2006). 
Here, the rHV3 was very stable under the condition of 
both 100°C and pH 2.5 for 30 min, with little hirudin 
inactivated, so the supernate of the fermentation broth 
was treated under this condition and almost 98.8% of the 










Figure 3. SDS-PAGE of hirudin product from the gel 
filtration chromatography. Left lane, Protein mark; 




wash with ammonium sulfate of 90% saturation, main 
pigments or small fragments were removed. These pre-
treatment methods gave the possibility of conciseness 
and efficiency to the total isolation process. 
Exact and brief activity measurement method was very 
important to the total isolation process (Marshak et al., 
1996). By the improved concentration gradient titration 
method, the standard deviation of the Sample C was 2.3 
ATU/ml, which was much lower than that of 15.2 ATU/ml 
by Markwardt method, so the degree of variation of the 
determined value by the improved method was much 
lower than that by the Markwardt method. The activity of 
the normative hirudin (Sample D) was determined as 
98±1.8 ATU/ml, which was near the known value 96 
ATU/ml from Sigma and the standard deviation of 1.8 
ATU/ml was much lower than that of 5.6 ATU/ml by 
Markwardt method. The degrees of variation of the 
determined value of other samples by the improved 
method were all also much lower. The precision by the 
improved method was 2ATU/ml, because 5 µl of 1 times 
thrombin solution could make the mixture coagulate in 1 
min. However, the lowest concentration of the thrombin 
solution was  5  times   (100  NIH/ml),  therefore, the  pre- 
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Figure 4. Sample activities by Markwardt’s titration method 
and by the improved titration method. The values were the 
means ± standard deviations, obtained from at least seven 
experiments. A, The supernatant of Hirudo medicinalis 
Linnaeus; B, the supernatant of W. pigra; C, The rHV3 
supernatant from zymotic fluid of the B. subtilis; D, normative 




cision measured by Markwardt method were rela-tively 
coarse (with ±10ATU/ml precision), for example, Sample 
B activitiy measured by Markwardt method was 10 
ATU/ml, but was only 2 ATU/ml by the improved method, 
obviously, the latter was more fine and accurate. 
There was only one kind of titration concentration in 
Markwardt method (100 NIH/ml), so when hirudin con-
centration was high, much more times of titration should 
be needed for coagulation and often in little floccule, not 
in big agglomerate. Sometimes several dozens of times 
of titration made the mixture not coagulate. One reason 
was that the fibrinogen solution became too thin to 
coagulate easily. Another reason was that too many times 
of titration made the feeble initial coagulation invisible 
and destroyed by shake and sometimes coagulation did 
not happen forever. Therefore, the activity value deter-
mined by Markwardt method was of higher variability, 
lower repeatability and accuracy.      
The result changed evidently when tempera-
ture differed. If it is below 37°C, the activity became on 
the high side. All the thrombin or fibrinogen solution 
should be prepared just before titration assay. In 
conclusion, the concise and efficient isolation line of the 
rHV3 from the B. subtilis was as follows: Fermentation 
supernate → heating at both 100°C and pH 2.5 for 30 
min → precipitation by ammonium sulfate with 90% 
saturation → gel filtration → pure products (Total recovery 
rate = 95% × 95% × 93% = 83.9% and the purity was  95%). 




By successively titrating several test tubes of the same 
sample with a series of thrombin concentration and 
gradually reducing the activity range of the sample, the 
optimum group of thrombin concentration was selected 
for the last steps titration, therefore, with this improved 
thrombin titration method and the hirudin activity was 
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